Taken together, these findings may have clinical implications for therapeutic strategies to use glucagon to activate the cAMP signaling molecule CREBH and increase hepatic Insig-2a abundance in the treatment of hepatic steatosis and hyperlipidemia. Here, CREB3L3 is linked to fatty liver disease.